Blood Res.  2021 Dec;56(4):259-265. 10.5045/br.2021.2021089.

Clinical features and outcomes of JAK2V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2V617F allele burden

• Lee AJ
• Kim SG
• Nam JY
• Yun J
• Ryoo HM
• Bae SH

• KMID: 2524084
• DOI: http://doi.org/10.5045/br.2021.2021089

Abstract

Background
JAK2mutation status is a well-known risk factor for thrombosis in patients with myeloproliferative neoplasms. However, the clinical usefulness of JAK2V617F allele burden is under investigation.
Methods
We retrospectively evaluated the impact of the JAK2V617F allele burden on clinical characteristics and outcomes of JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). The JAK2V617F allele burden was measured using sequencing.
Results
Altogether, 127 patients with JAK2V617F mutation (PV, N=61; ET, N=66) were included in this study. JAK2V617F allele burdens were positively correlated with white blood cell counts, hemoglobin values, lactate dehydrogenase levels, and platelet counts. The median values of JAK2V617F allele burden in patients with PV and ET were 58% and 30%, respectively. A JAK2V617F allele burden of ≥30%, older age, and a higher hemoglobin level were risk factors for thrombotic events in ET. In patients with PV, older age was the only thrombotic risk factor. The 8-year probabilities of overall survival (OS) were 82.9% in all patients. A high JAK2V617F allele burden (≥58%) was associated with poor OS in patients with PV. For the patients with ET, the difference in 8-year OS based on the JAK2V617F allele burden was not significant.
Conclusion
The JAK2V617F allele burden was correlated with hematologic parameters and clinical outcomes. Assessing the JAK2V617F allele burden can be helpful in predicting the thrombotic risk and disease course in patients with JAK2V617F-positive PV and ET.

Keyword

JAK2; Thrombosis; Polycythemia; Thrombocythemia; Essential thrombocythemia; Polycythemia vera

Figure

• 

  Fig. 1 Survival according to JAK2 V617F allele burden. Overall survival (OS) in patients with PV (A), thrombosis free survival (TFS) in patients with PV (B), OS in patients with ET (C), TFS in patients with ET (D).

Reference

1. Hultcrantz M, Kristinsson SY, Andersson TM, et al. 2012; Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 30:2995–3001. DOI: 10.1200/JCO.2012.42.1925. PMID: 22802311. PMCID: PMC3417050.

2. Tefferi A, Guglielmelli P, Larson DR, et al. 2014; Long-term survival and blast transformation in molecularly annotated essential thrombo-cythemia, polycythemia vera, and myelofibrosis. Blood. 124:2507–13. DOI: 10.1182/blood-2014-05-579136. PMID: 25037629. PMCID: PMC4199952.

3. Tefferi A, Barbui T. 2020; Polycythemia vera and essential thrombo-cythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 95:1599–613. DOI: 10.1002/ajh.26008. PMID: 32974939.

4. Rumi E, Pietra D, Ferretti V, et al. 2014; JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 123:1544–51. DOI: 10.1182/blood-2013-11-539098. PMID: 24366362. PMCID: PMC3945864.

5. Lee MW, Ryu H, Song IC, Lee HJ, Yun HJ, Jo DY. 2020; Outcomes of patients with essential thrombocythemia and unnoticed thrombocytosis prior to diagnosis. Blood Res. 55:281–2. DOI: 10.5045/br.2020.2020239. PMID: 33303708. PMCID: PMC7784122.

6. Barbui T, Finazzi G, Falanga A. 2013; Myeloproliferative neoplasms and thrombosis. Blood. 122:2176–84. DOI: 10.1182/blood-2013-03-460154. PMID: 23823316.

7. Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. 2019; A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 19:184. DOI: 10.1186/s12885-019-5387-9. PMID: 30819138. PMCID: PMC6393965.

8. Baxter EJ, Scott LM, Campbell PJ, et al. 2005; Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–61. DOI: 10.1016/S0140-6736(05)71142-9. PMID: 15781101.

9. James C, Ugo V, Le Couédic JP, et al. 2005; A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144–8. DOI: 10.1038/nature03546. PMID: 15793561.

10. Kralovics R, Passamonti F, Buser AS, et al. 2005; A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 352:1779–90. DOI: 10.1056/NEJMoa051113. PMID: 15858187.

11. Levine RL, Wadleigh M, Cools J, et al. 2005; Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombo-cythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–97. DOI: 10.1016/j.ccr.2005.03.023. PMID: 15837627.

12. Barbui T, Finazzi G, Carobbio A, et al. 2012; Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 120:5128–33. DOI: 10.1182/blood-2012-07-444067. PMID: 23033268.

13. Vannucchi AM, Pieri L, Guglielmelli P. 2011; JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2:21–32. DOI: 10.1177/2040620710394474. PMID: 23556073. PMCID: PMC3573388.

14. Passamonti F, Rumi E, Pietra D, et al. 2010; A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 24:1574–9. DOI: 10.1038/leu.2010.148. PMID: 20631743.

15. Borowczyk M, Wojtaszewska M, Lewandowski K, et al. 2015; The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res. 135:272–80. DOI: 10.1016/j.thromres.2014.11.006. PMID: 25559461.

16. Passamonti F, Rumi E. 2009; Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica. 94:7–10. DOI: 10.3324/haematol.2008.001271. PMID: 19118374. PMCID: PMC2625431.

17. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. 2008; Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 22:1299–307. DOI: 10.1038/leu.2008.113. PMID: 18496562.

18. Carobbio A, Finazzi G, Antonioli E, et al. 2009; JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombo-cythemia and polycythemia vera. Exp Hematol. 37:1016–21. DOI: 10.1016/j.exphem.2009.06.006. PMID: 19559071. PMCID: PMC2746993.

19. Vannucchi AM, Antonioli E, Guglielmelli P, et al. 2007; Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 21:1952–9. DOI: 10.1038/sj.leu.2404854. PMID: 17625606.

20. Arber DA, Orazi A, Hasserjian R, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.

21. Antonioli E, Guglielmelli P, Poli G, et al. 2008; Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 93:41–8. DOI: 10.3324/haematol.11653. PMID: 18166784.

22. Tefferi A, Vainchenker W. 2011; Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 29:573–82. DOI: 10.1200/JCO.2010.29.8711. PMID: 21220604.

23. Bakker E. 2006; Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessed. Clin Chem. 52:557–8. DOI: 10.1373/clinchem.2005.066068. PMID: 16595822.

24. Bench AJ, White HE, Foroni L, et al. 2013; Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 160:25–34. DOI: 10.1111/bjh.12075. PMID: 23057517.

25. Kinz E, Leiherer A, Lang AH, Drexel H, Muendlein A. 2015; Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. Int J Lab Hematol. 37:217–24. DOI: 10.1111/ijlh.12269. PMID: 24963593.